{
    "clinical_study": {
        "@rank": "15024", 
        "arm_group": [
            {
                "arm_group_label": "Lacosamide 30-minute iv", 
                "arm_group_type": "Experimental", 
                "description": "A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial)."
            }, 
            {
                "arm_group_label": "Lacosamide 60-minute iv", 
                "arm_group_type": "Experimental", 
                "description": "60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial)."
            }, 
            {
                "arm_group_label": "Lacosamide oral tablet", 
                "arm_group_type": "Experimental", 
                "description": "Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be conducted to compare the pharmacokinetics of Lacosamide (LCM) following a\n      single 30-minute or 60-minute iv infusion of LCM 200 mg with those following a single oral\n      dose of LCM 200 mg in healthy Japanese subjects."
        }, 
        "brief_title": "Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Japanese male and female volunteers with the age between 20 and 55 years old\n\n        Exclusion Criteria:\n\n          -  Subject has participated or is participating in any other clinical studies of\n             investigational drug or another investigational medical product within the last 3\n             months\n\n          -  Subject has a history (within 6 months) before screening visit of chronic alcohol\n             and/or drug abuse and/or has smoked and/or has a history or presence of\n             cardiovascular, respiratory, hepatic, renal, GI, endocrinological, or neurological\n             disorders\n\n          -  Subject has a history of suicide attempt or current active suicidal ideation\n\n          -  Subject has experienced a myocardial infarction and/or made a blood donation or any\n             other blood loss more than 400 ml in the last 3 months\n\n          -  Subject is pregnant or nursing\n\n          -  Subject is not healthy (eg, taking any drug treatments, having any medical or\n             emotional/psychological problems, a drug/alcohol abuse, having abnormal safety\n             parameters and/or was positive for  HIV, HBsAg, HCV)\n\n          -  Subject has an excessive use of alcohol or/and cigarettes and/or caffeine and/or\n             abnormal diet and/or has taken grapefruit or grapefruit drink within 7 days before\n             intake of Investigational Medicinal Product (IMP)\n\n          -  Subject has a clinically significant abnormality in the 12-lead Electrocardiogram\n             (ECG)\n\n          -  Subject is having clinically relevant drug hypersensitivity to any components of the\n             investigational medicinal product"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986608", 
            "org_study_id": "EP0036", 
            "secondary_id": "2012-003084-21"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lacosamide 30-minute iv", 
                    "Lacosamide 60-minute iv"
                ], 
                "description": "Strength: 10 mg/mL for infusion\nForm: solution for infusion\nDosage: 200 mg, single dose\nDuration: 30-minute infusion or 60-minute infusion", 
                "intervention_name": "Lacosamide infusion", 
                "intervention_type": "Drug", 
                "other_name": "Vimpat"
            }, 
            {
                "arm_group_label": "Lacosamide oral tablet", 
                "description": "Strength: 200 mg\nForm: film-coated tablet\nDosage: 200 mg, single dose\nDuration: single oral intake", 
                "intervention_name": "Lacosamide oral", 
                "intervention_type": "Drug", 
                "other_name": "Vimpat"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lacosamide", 
            "Vimpat", 
            "Bioequivalence", 
            "Bioavailability", 
            "Japanese"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Harrow", 
                    "country": "United Kingdom", 
                    "state": "Middlesex"
                }, 
                "name": "001"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single Center Open-label, Randomized, Single-dose, 3-way Crossover Study to Compare the Safety, Tolerability, and Pharmacokinetics of Lacosamide Administered as Oral Tablet or Intravenous Infusion in Healthy Japanese Subjects", 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The value of the maximum plasma concentration will be directly obtained from the observed plasma concentration versus time curves.", 
                "measure": "Maximum plasma concentration of Lacosamide (Cmax) after oral and intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration of Lacosamide (AUC 0-t) after oral and intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986608"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The area under the curve extrapolated to infinity is calculated as the sum of AUC(0-t) and a residual part extrapolated to infinite time.", 
                "measure": "Area under the plasma concentration-time curve from zero up to infinity (AUC) after oral and intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Time to reach a maximum plasma concentration (tmax)  after oral and intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Mean residence time (MRT) after oral and intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Rate constant of elimination (\u03bbz) after oral and intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Terminal half-life (t1/2) after oral and intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Apparent total body clearance (CL/F) after oral administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Total body clearance (CL) after intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Apparent volume of distribution (Vz/F) after oral administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }, 
            {
                "measure": "Volume of distribution (Vz) after intravenous administration of Lacosamide", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB Pharma SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}